| Next 10 |
Ad
ELEV News and Press Elevation Oncology Inc.
News | Elevation Oncology Inc. (NASDAQ:ELEV)
-
2023-05-26 12:04:42 ET Elevation Oncology ( NASDAQ: ELEV ) is up 61% in Friday trading after release promising phase 1 data from a dose-escalation study on a solid tumors antibody-drug conjugate. The candidate, SYSA1801, targets the Claudin18.2 protein, which is seen in ma...
-
2023-05-26 10:05:44 ET Gainers: Elevation Oncology ( ELEV ) +58% . Arcus Biosciences ( RCUS ) +26% . Healthcare Triangle ( HCTI ) +17% . PDS Biotechnology ( PDSB ) +16% . NEXGEL ( NXGL ) +12% . Losers: Tilray Brands (...
-
2023-05-26 08:34:32 ET Onfolio Holdings ( ONFO ) +62% Completes Development of Generative AI Search Tool. Elevation Oncology ( ELEV ) +58% . Quhuo Limited ( QH ) +37% Sector Exceeded RMB12 Million in Sales During the Labor Day Holiday, Achieving Impre...
-
2023-05-25 18:21:14 ET If you’re like many retail traders in the stock market today, penny stocks are a popular prospect. This article looks at some of the most active penny stocks today with late-breaking momentum. They could also be on the radar of traders before next week. But...
-
2023-05-25 18:08:05 ET Gainers: Elevation Oncology ( ELEV ) +45% . Marvell Technology ( MRVL ) +18% . Workday ( WDAY ) +8% . Veritone ( VERI ) +6% . Paramount Global ( PARA ) +6% . Losers: Nano Labs ( NA ) -12...
-
2023-05-19 10:04:48 ET Gainers: Lucy Scientific Discovery ( LSDI ) +51% . Bioventus ( BVS ) +44% . Mallinckrodt ( MNK ) +28% . 180 Life Sciences ( ATNF ) +28% . Stereotaxis ( STXS ) +25% . Losers: Enveric Biosciences ( ENVB ...
-
2023-05-15 09:48:28 ET Elevation Oncology press release ( NASDAQ: ELEV ): Q1 GAAP EPS of -$0.72. As of March 31, 2022, the Company had cash, cash equivalents and marketable securities totaling $73.9 million, compared to $90.3 million as of December 31, 2022. ...
-
Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business Achievements PR Newswire Partner CSPC Pharmaceutical Group Limited's ongoing Phase 1 SYSA1801 (EO-3021) clinical trial data selected for poster presentation and poster discussi...
-
Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 PR Newswire NEW YORK , April 26, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology comp...
-
Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023 PR Newswire EO-3021 demonstrated anti-tumor activity in preclinical models expressing varying levels of Claudin 18.2 ...
Stock Information
Elevation Oncology Inc. Company Name:
ELEV Stock Symbol:
NASDAQ Market:
Elevation Oncology Inc. Website:
Get ELEV Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
